keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromosome Positive Chronic Granulocytic Leukemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 33.00 | |
10 mg | In stock | $ 53.00 | |
25 mg | In stock | $ 79.00 | |
50 mg | In stock | $ 108.00 | |
100 mg | In stock | $ 162.00 | |
500 mg | In stock | $ 328.00 |
Description | Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromosome Positive Chronic Granulocytic Leukemia. |
Targets&IC50 | Csk:314 nmol/L, Abl kinase:2.4 nmol/L |
In vitro | Bosutinib hydrate(SKI-606)was a inhibitor of two Src-related kinases (i.e., Fgr and Lyn with IC50s of 0.174 and 0.850 nmol/L, respectively)[2]. |
In vivo | Administration of Bosutinib hydrate(SKI-606) at doses of 75 mg/kg twice daily or 150 mg/kg once daily can promote complete regression of human K562 xenografts for up to 40 days[2]. |
Synonyms | PF-5208763 hydrate, PF-05208763 hydrate, SKI-606 hydrate |
Molecular Weight | 548.46 |
Formula | C26H31Cl2N5O4 |
CAS No. | 918639-08-4 |
keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (145.86 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bosutinib hydrate 918639-08-4 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Src Bcr-Abl PF-5208763 hydrate PF-05208763 hydrate SKI-606 hydrate inhibitor inhibit